SCHEMBL6256451

SCHEMBL6256451

COC(=O)c1ccc(CNc2ccccc2OCc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.60
▸ CA2 P00918 2/20 0.60
▸ LMNA P02545 3/20 0.57
▸ MAPT P10636 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ BRD4 O60885 1/20 0.56
▸ RXRA P19793 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ HPGD P15428 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ GAA P10253 1/20 0.50
▸ NPC1 O15118 2/20 0.49
▸ CASP3 P42574 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255821 0.88 HPGD (0.61) MAPTL3MBTL1KMT2AMEN1BRD4
SCHEMBL15761720 0.85 CA1 (0.60) CA1CA2LMNAMAPTRAB9A
SCHEMBL19946528 0.81 MAPT (0.59) LMNAMAPTRAB9AL3MBTL1KMT2A
SCHEMBL16211289 0.80 CA1 (0.53) CA1CA2LMNAMAPTRAB9A
SCHEMBL29245141 0.80 CA1 (0.77) CA1CA2MAPTRAB9AKMT2A
SCHEMBL2575159 0.79 MAPT (0.64) LMNAMAPTRAB9AL3MBTL1KMT2A
SCHEMBL28376684 0.79 MAPT (0.63) LMNAMAPTRAB9AL3MBTL1KMT2A
SCHEMBL15761734 0.78 CA1 (0.61) CA1CA2LMNAMAPTRAB9A
SCHEMBL8406671 0.78 HTR1A (0.66) LMNAMAPTRAB9AL3MBTL1KMT2A
SCHEMBL15761771 0.78 CA1 (0.70) CA1CA2MAPTRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0752421-B1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ASTRAZENECA AB (SE) 2005-10-12 — — EP disclosed
US-6787562-B2 ANALGESICS; OSTEOPOROSIS ZENECA LTD. (GB) 2004-09-07 — — US disclosed
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists SYNGENTA LIMITED (GB) 2003-07-24 — — US disclosed
US-6057345-A ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF ZENECA LIMITED (GB) 2000-05-02 — — US disclosed
US-5834468-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES ZENECA LIMITED (GB) 1998-11-10 — — US disclosed
EP-0752421-A1 Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists ZENECA LIMITED (GB) 1997-01-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139418-A1 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists PTGER1, PTGDR, PTGER2 CA1 3853/4885CA2 2455/4885LMNA 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback